HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

DNA Virus Infections

Diseases caused by DNA VIRUSES.
Also Known As:
Infections, DNA Virus; DNA Virus Infection; Infection, DNA Virus; Virus Infection, DNA; Virus Infections, DNA
Networked: 139 relevant articles (3 outcomes, 11 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Leukemia
2. Infections
3. Virus Diseases (Viral Diseases)
4. Bites and Stings (Sting)
5. Acquired Immunodeficiency Syndrome (AIDS)

Experts

1. Shu, Hong-Bing: 6 articles (10/2021 - 07/2012)
2. Zheng, Chunfu: 3 articles (01/2022 - 01/2017)
3. Ferguson, Brian J: 3 articles (01/2020 - 01/2013)
4. Zhang, Xiaobo: 3 articles (09/2019 - 04/2012)
5. Chen, Zhijian J: 3 articles (09/2013 - 02/2013)
6. Sun, Lijun: 3 articles (09/2013 - 02/2013)
7. Wu, Jiaxi: 3 articles (09/2013 - 02/2013)
8. De Clercq, Erik: 3 articles (01/2013 - 09/2008)
9. Karijolich, John: 2 articles (06/2022 - 12/2019)
10. Knipe, David M: 2 articles (01/2022 - 01/2018)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to DNA Virus Infections:
1. NucleosidesIBA
07/01/1977 - "Certain D-arabinosyl nucleosides, notably arabinosyl cytosine (araC) and arabinosyl adenine (araA), are useful in the treatment of certain leukemias and some DNA virus infections, respectively. "
12/01/1976 - "Certain D-arabinosyl nucleosides, notably D-arabinosyl cytosine (araC) and D-arabinosyl adenine (araA), are useful in the treatment of certain leukemias and some DNA virus infections, respectively. "
01/01/2010 - "This has prompted me to highlight some of the hallmarks that played an important role in my own search of a selective therapy of viral infections: i.e., the induction of interferon by double-stranded RNA [such as poly(I).poly(C)], allowing the cloning and expression of beta-interferon; the discovery of the reverse transcriptase (RT) (and HIV as a retrovirus depending for its replication on RT), allowing the identification and development of a wide variety of RT inhibitors, nowadays used for the treatment of AIDS; the specificity of herpesvirus inhibitors such as acyclovir and BVDU, in the treatment of HSV and VZV infections; the role of acyclic nucleoside phosphonates (tenofovir, adefovir and cidofovir) in the treatment of HIV, HBV and DNA virus infections; and that of the NNRTIs (leading from TIBO to rilpivirine) as an essential part of the current anti-HIV drug cocktails. "
09/01/2008 - "Foremost among the newly described antiviral agents that may be developed into drugs are, for the treatment of human papilloma virus (HPV) infections, cPrPMEDAP; for the treatment of herpes simplex virus (HSV) infections, BAY 57-1293; for the treatment of varicella-zoster virus (VZV) infections, FV-100 (prodrug of Cf 1743); for the treatment of cytomegalovirus (CMV) infections, maribavir; for the treatment of poxvirus infections, ST-246; for the treatment of hepatitis B virus (HBV) infections, tenofovir disoproxil fumarate (TDF) (which in the meantime has already been approved in the EU); for the treatment of various DNA virus infections, the hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE) prodrugs of cidofovir; for the treatment of orthomyxovirus infections (i.e., influenza), peramivir; for the treatment of hepacivirus infections (i.e., hepatitis C), the protease inhibitors telaprevir and boceprevir, the nucleoside RNA replicase inhibitors (NRRIs) PSI-6130 and R1479, and various non-nucleoside RNA replicase inhibitors (NNRRIs); for the treatment of human immunodeficiency virus (HIV) infections, integrase inhibitors (INIs) such as elvitegravir, nucleoside reverse transcriptase inhibitors (NRTIs) such as apricitabine, non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as rilpivirine and dapivirine; and for the treatment of both HCV and HIV infections, cyclosporin A derivatives such as the non-immunosuppressive Debio-025."
04/01/2002 - "This includes, for the treatment of HIV infections, virus adsorption inhibitors (cosalane derivatives, cyanovirin-N), co-receptor antagonists (TAK-779, AMD3100), viral fusion inhibitors (pentafuside T-20, betulinic acid derivatives), viral uncoating inhibitors (azodicarbonamide), nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs: emtricitabine, amdoxovir, dOTC, d4TMP prodrugs, tenofovir disoproxil fumarate), non-nucleoside reverse transcriptase inhibitors (NNRTIs: thiocarboxanilide UC-781, capravirine, SJ-3366, DPC 083, TMC 125/R165335), integrase inhibitors (diketo acids), transcription inhibitors (temacrazine, flavopiridol), protease inhibitors (atazanavir, mozenavir, tipranavir); for the treatment of RSV and paramyxovirus infections, viral fusion inhibitors (R170591, VP-14637, NMS03); for the treatment of picornavirus infections, viral uncoating inhibitors (pleconaril); for the treatment of pesti- (hepaci-, flavi-) virus infections, RNA replicase inhibitors (VP-32947); for the treatment of herpesvirus (HSV, VZV, CMV) infections, DNA polymerase inhibitors (A-5021, L- and D-cyclohexenylguanine); for the treatment of VZV infections, bicyclic furopyrimidine analogues; for the treatment of CMV infections, fomivirsen; for the treatment of DNA virus infections at large (papilloma-, polyoma-, herpes-, adeno- and poxvirus infections), cidofovir; for the treatment of influenza, neuraminidase inhibitors (zanamivir, oseltamivir, RWJ-270201); for the treatment of HBV infections, adefovir dipivoxil; for the treatment of HBV and HCV infections, N-glycosylation inhibitors (N-nonyl-deoxynojirimycin); and, finally, IMP dehydrogenase inhibitors and S-adenosylhomocysteine hydrolase inhibitors, for the treatment of various virus infections, including hemorrhagic fever virus infections."
2. CytosineIBA
3. AdenineFDA LinkGeneric
4. DNA (Deoxyribonucleic Acid)IBA
5. InterferonsIBA
6. Antiviral Agents (Antivirals)IBA
7. RNA (Ribonucleic Acid)IBA
8. Interferon Type IIBA
9. A-Form DNA (A-DNA)IBA
10. MicroRNAs (MicroRNA)IBA

Therapies and Procedures

1. Hematopoietic Stem Cell Transplantation
2. Therapeutics
3. Off-Label Use
4. Liver Transplantation
5. Transplantation